Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2017 | Phase III, randomized, placebo-controlled, double-blind trial of motesanib (AMG-706) in combination with paclitaxel and carboplatin in east asian patients with advanced nonsquamous non-small-cell lung cancer | Kubota K; Asato T; Hara K; Yoshioka H; Oshita F; Hida T; Yoh K; Nakagawa K; Hayashi H; Kaneda H; Kato T; Yamada K; Ichinose Y; Tanaka H; Park K; Cho E.K; Lee K.-H; Lin C.-B; CHIH-HSIN YANG | Journal of Clinical Oncology | 32 | 28 | |
2013 | Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas | Wu P.-F.; Huang W.-C.; CHIH-HSIN YANG ; YEN-SHEN LU ; JIN-YUAN SHIH ; SHANG-GIN WU ; CHING-HUNG LIN ; ANN-LII CHENG | Journal of Neuro-Oncology | 8 | 5 | |
2017 | Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer | Jenkins S; CHIH-HSIN YANG ; Ramalingam S.S; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne P.A; Mitsudomi T; Goss G.D. | Journal of Thoracic Oncology | 224 | 204 | |
2011 | Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC | Medema R.H.; CHIA-CHI LIN ; CHIH-HSIN YANG | Clinical Cancer Research | 60 | 58 | |
1996 | Polyprenoic acid in hepatocellular carcinoma | CHIH-HSIN YANG ; ANN-LII CHENG | New England Journal of Medicine | 0 | 0 | |
2016 | Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer | Gadgeel S.M; Shaw A.T; Govindan R; Gandhi L; Socinski M.A; Camidge D.R; De Petris L; Kim D.-W; Chiappori A; Moro-Sibilot D.L; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; CHIH-HSIN YANG ; Han J.-Y; Bordogna W; Golding S; Zeaiter A; Ou S.-H.I. | Journal of Clinical Oncology | 163 | 142 | |
2020 | Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer | Ou S.-H.I; Gadgeel S.M; Barlesi F; CHIH-HSIN YANG ; De Petris L; Kim D.-W; Govindan R; Dingemans A.-M; Crino L; Léna H; Popat S; Ahn J.S; Dansin E; Mitry E; Müller B; Bordogna W; Balas B; Morcos P.N; Shaw A.T. | Lung Cancer | 23 | 10 | |
2017 | Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer | CHIH-HSIN YANG ; Ou S.-H.I; De Petris L; Gadgeel S; Gandhi L; Kim D.-W; Barlesi F; Govindan R; Dingemans A.-M.C; Crino L; Lena H; Popat S; Ahn J.S; Dansin E; Golding S; Bordogna W; Balas B; Morcos P.N; Zeaiter A; Shaw A.T. | Journal of Thoracic Oncology | 78 | 56 | |
2017 | The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC | Manegold C; Dingemans A.-M.C; Gray J.E; Nakagawa K; Nicolson M; Peters S; Reck M; Wu Y.-L; Brustugun O.T; Crinò L; Felip E; Fennell D; Garrido P; Huber R.M; Marabelle A; Moniuszko M; Mornex F; Novello S; Papotti M; Pérol M; Smit E.F; Syrigos K; van Meerbeeck J.P; van Zandwijk N; Chih-Hsin CHIH-HSIN YANG ; Zhou C; Vokes E. | Journal of Thoracic Oncology | 184 | 168 | |
2020 | Precision Management of Advanced Non-Small Cell Lung Cancer | CHING-YAO YANG ; CHIH-HSIN YANG ; PAN-CHYR YANG | Annual Review of Medicine | 95 | 93 | |
2016 | Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity | Ballard P; Yates J.W.T; Yang Z; Kim D.-W; CHIH-HSIN YANG ; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress K.S; Jänne P.A; Cross D. | Clinical Cancer Research | 550 | 490 | |
2006 | Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients | Chang G.-C.; Tsai C.-M.; Chen K.-C.; CHONG-JEN YU ; JIN-YUAN SHIH ; Yang T.-Y.; Lin C.-P.; Hsu J.-Y.; Chiu C.-H.; Perng R.-P.; PAN-CHYR YANG ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 44 | 35 | |
2019 | Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer | Woodford R; Loh Y; Lee J; Cooper W; Marschner I; Lewis C.R; Millward M; Lord S; Gralla R.J; CHIH-HSIN YANG ; Mok T; Lee C.K. | Future Oncology | 4 | 4 | |
2008 | Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers | JO-PAI CHEN ; Lo Y.; CHONG-JEN YU ; CHIUN HSU ; JIN-YUAN SHIH ; CHIH-HSIN YANG | Lung Cancer | 12 | 7 | |
2012 | Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer | KANG-YI SU ; Chen H.-Y.; Li K.-C.; Kuo M.-L.; CHIH-HSIN YANG ; Chan W.-K.; Ho B.-C.; Chang G.-C.; JIN-YUAN SHIH ; SUNG-LIANG YU ; PAN-CHYR YANG | Journal of Clinical Oncology | 464 | 428 | |
2000 | The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane | Rocchi E; Khodjakov A; Volk E.L; CHIH-HSIN YANG ; Litman T; Bates S.E; Schneider E. | Biochemical and Biophysical Research Communications | 168 | 147 | |
2016 | Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer | Hsiue E.H.-C; JIH-HSIANG LEE ; CHIA-CHI LIN ; CHIH-HSIN YANG | Expert Review of Molecular Diagnostics | 15 | 14 | |
2021 | Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan | SHANG-GIN WU ; WEI-YU LIAO ; KANG-YI SU ; SUNG-LIANG YU ; YEN-LIN HUANG ; CHONG-JEN YU ; CHIH-HSIN YANG ; JIN-YUAN SHIH | JTO Clinical and Research Reports | 16 | 0 | |
2019 | Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients – A Taiwanese study | Wu T.-H.; Lee L.J.-H.; CHANG-TSU YUAN ; WEI-WU CHEN ; CHIH-HSIN YANG | Journal of the Formosan Medical Association | 7 | 6 | |
2015 | The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia | HUNG-YANG KUO ; ZHONG-ZHE LIN ; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO ; CHIUN HSU ; WEN-FANG CHENG ; ANN-LII CHENG ; CHIH-HSIN YANG ; Lai M.-S. | Oncologist | 10 | 10 |